Oragenics Inc is a biotechnology company focused on the development and licensure of innovative products and technologies for improving human health.
Revenue (Most Recent Fiscal Year) | $0.04M |
Net Income (Most Recent Fiscal Year) | $-20.66M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | -- |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.76 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -54858.84% |
Net Margin (Trailing 12 Months) | -- |
Return on Equity (Trailing 12 Months) | -397.35% |
Return on Assets (Trailing 12 Months) | -246.95% |
Current Ratio (Most Recent Fiscal Quarter) | 2.15 |
Quick Ratio (Most Recent Fiscal Quarter) | 2.15 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
Inventory Turnover (Trailing 12 Months) | -- |
Book Value per Share (Most Recent Fiscal Quarter) | $0.61 |
Earnings per Share (Most Recent Fiscal Quarter) | -- |
Earnings per Share (Most Recent Fiscal Year) | -- |
Diluted Earnings per Share (Trailing 12 Months) | $-9.25 |
Exchange | NYSEMKT |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 4.48M |
Free Float | 3.38M |
Market Capitalization | $4.84M |
Average Volume (Last 20 Days) | 0.06M |
Beta (Past 60 Months) | 0.31 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 24.60% |
Percentage Held By Institutions (Latest 13F Reports) | 18.71% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |